First Tracks Biotherapeutics (TRAX) Registration filing summary

Company overview and business model

• Clinical-stage biotech developing antibody therapies that modulate immune pathways in autoimmune and inflammatory diseases, with potential applications across gastroenterology, rheumatology, dermatology and respiratory medicine.

• Pipeline: ANB033, a CD122 antagonist for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter for rheumatoid arthritis; and ANB101, a BDCA2 modulator.

• Strategy centers on efficient early-stage trials, translational data to differentiate candidates, selective partnerships for global development and commercialization while retaining key-market rights, and licensing or discovering additional antibody targets.

• No products approved for commercial sale and no product-sales revenue; relies on third parties for clinical and commercial manufacturing, trials and related services.

Financial performance and metrics

• Net loss was $83.9M for 6M 2026 vs. $89.6M for 6M 2025; R&D expense was $59.6M vs. $80.7M, while G&A expense was $28.1M vs. $16.4M.

• FY2025 net loss was $166.1M vs. $163.7M in FY2024; FY2025 R&D expense was $139.6M vs. $152.3M and G&A expense was $39.4M vs. $28.8M.

• Cash and cash equivalents were $168.0M at June 30, 2026; cash, equivalents and investments totaled $311.6M at Dec. 31, 2025 vs. $420.8M at Dec. 31, 2024.

• Management expects existing cash, equivalents and investments to fund the current operating plan beyond the next 12 months; estimates depend on assumptions and spending may exceed forecasts.

• Operating cash used was $64.5M in 6M 2026 vs. $83.6M in 6M 2025; FY2025 operating cash used was $142.9M vs. $125.8M in FY2024.

Use of proceeds and capital allocation

• No proceeds from the registered resale will go to the issuer; selling stockholders receive resale proceeds, while registration expenses are borne by the issuer.

• The October 2026 private placement generated approximately $200M gross proceeds before placement fees and expenses; cash, equivalents and investments are expected to fund the operating plan beyond the next 12 months.

• Capital allocation plans include approximately $165M for ANB033 clinical trials and development through Phase 1b in celiac disease and eosinophilic esophagitis, Phase 2 in vitiligo and one additional indication, and late-stage celiac development; remainder for general corporate purposes.

• Primary capital needs include external clinical and preclinical R&D, manufacturing, laboratory supplies, personnel, legal, patent and regulatory costs, and overhead; additional financing or partnerships may be needed.